With a mild touch and manifest efficacy, ABiC™ performed with the iTrack™ surgical system is a comprehensive minimally invasive glaucoma surgery that can effectively reduce IOP and eliminate or reduce the medication burden. Restorative and atraumatic, ABiC™ can be performed across the entire glaucoma disease process – and in conjunction with other treatments and MIGS options.
Performed with the iTrack™ surgical system from Ellex, ABiC™ comprehensively addresses blockages in the collector channels and flushes the outflow channels without damaging tissue and without leaving behind a stent or shunt.
ABiC™ re-establishes the eye’s natural outflow system by accessing, catheterizing and viscodilating the trabecular meshwork, Schlemm’s canal, and the distal outflow system. 360º viscodilation of Schlemm’s canal can separate the compressed tissue planes of the trabecular meshwork, causing any herniated inner wall tissue to withdraw from the collector channels. This complements the mechanic opening achieved via the circumnavigation of the iTrack™ microcatheter through Schlemm’s canal.
The most defining aspect of ABiC™ is its comprehensive approach. To date, ABiC™ is the only minimally invasive glaucoma surgery that successfully and comprehensively addresses all aspects of potential outflow resistance. This contrasts with other MIGS procedures, where only a segment of Schlemm’s canal is addressed, or where the trabecular meshwork is targeted in isolation. When using a stent-based MIGS there is a risk that the area of blockage will be missed or sub optimally treated.
ABiC™ performed with the iTrack™ surgical system is both safe and effective. On average, it achieves a reduction in IOP of 30% and a 50% reduction in medication dependence.1
Intuitive and efficient, ABiC™ can be performed as a standalone procedure, or in conjunction with cataract surgery.
ABiC™ can also be deployed synergistically with Selective Light Therapy (SLT) to control IOP by restoring the natural outflow pathways. SLT stimulates cellular regeneration to create a healthier, more porous trabecular meshwork structure, and achieves an average 30% reduction in IOP when used as a first-line therapy. Additionally, ABiC™ can be used in conjunction with other MIGS devices or treatments — and, as an atraumatic procedure, it does not preclude future treatment options.
1. 228-eye ABiC 12-Month Case Series Data, presented at ASCRS 2016. Data on file. Ellex Medical.
This article discusses the role of ABiC, which has grown into a procedure that is effective, safe and easily combined with other MIGS interventions. Contributing authors include Mahmoud Khaimi, MD (USA), Norbert Koerber, MD, PhD (Germany), Mark Gallardo, MD (USA), Sev Teymoorian, MD (USA) and Leon Au, MD (UK).
The March 2018 issue of CRST featured a case study by Dr. David Lubeck in which ABiC was successfully performed in a patient post-SLT and iStent – speaking to the versatility of iTrack in clinical practice.
